Advertisement

Related Videos

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Amit Sanyal, MD: A Clinician’s Perspective

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

Deborah Collyar: What's In It for Patients?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Oct
30
Today In Oncology
How Medicare Advantage and Traditional Medicare Influence Palliative and Hospice Care Implementation
Tarlatamab Plus Durvalumab as First-Line Maintenance in Extensive-Stage SCLC
TALENT Neoadjuvant T-DXd in HER2-Low Early Breast Cancer
Adding a Chatbot to Cancer Predisposition Visits Improves Risk Knowledge in AYAs
Substudy Validates Perioperative Approach of Systemic Therapy With Radical Prostatectomy
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo